Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)

Lupus

Volumn 24, Issue 9, 2015, Pages 927-934

  Amigo, M C ^a   Goycochea Robles, M V ^b   Espinosa Cuervo, G ^b   Medina, G ^b   Barragan Garfias J A ^c   Vargas, A ^d   Jara, L Javier ^b  

^a AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Instituto Mexicanodel Seguro Social   (Mexico)

^d INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Antiphospholipid syndrome; Damage index; Hughes syndrome

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY BETA 2 GLYCOPROTEIN 1; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; RITUXIMAB; UNCLASSIFIED DRUG; PHOSPHOLIPID ANTIBODY;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLINDNESS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONSTRUCT VALIDITY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DEPRESSION; DEVELOPMENT AND INITIAL VALIDATION OF A DAMAGE INDEX; DISEASE ASSESSMENT; DYSLIPIDEMIA; FEMALE; HEALTH STATUS; HEART INFARCTION; HEART VALVE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA DISEASE; RETINAL OCCLUSIVE VESSEL DISEASE; SKIN ULCER; THROMBOSIS; VISUAL ANALOG SCALE; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMORBIDITY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84937834095     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315576858     Document Type: Article

References (24)

1. Miyakis S, Lockshin MD, Atsumi T,. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Cervera R, Piette JC, Font J,. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
3. Alarcón-Segovia D, Pérez-Ruiz A, Villa AR,. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2000; 15: 157-161.
4. Amigo MC,. Prognosis in antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27: 661-669.
5. Erkan D, Yazici Y, Sobel R, Lockshin MD,. Primary antiphospholipid syndrome: Functional outcome after 10 years. J Rheumatol 2000; 27: 2817-2821.
6. Amigo MC, García-Torres R, Kidney disease in antiphospholipid syndrome. In: Khamashta MA, (ed). Hughes syndrome: Antiphospholipid syndrome, 2nd ed. London: Springer-Verlag, 2006, pp. 99-111.
7. Grika EP, Ziakas PD, Zintaras E,. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516-523.
8. Tektonidou MG, Ioannidis JP, Boki KA,. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 2000; 93: 523-530.
9. Cervera R, Serrano R, Pons-Estel GJ,. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. Epub ahead of print 24 January 2014. DOI: 10.1136/annrheumdis-2013-204838.
10. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C,. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
11. Gladman D, Ginzler E, Goldsmith C,. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 1996; 39: 363-369.
12. Streiner DL, Norman GR,. Health measurement scales: A practical guide to their development and use, 2nd ed. New York: Oxford University Press Inc, 2003, pp. 144-154.
13. Feinstein AR,. Clinimetrics, London: Yale University Press, 1987, pp. 194-201. 4,5.
14. Amigo MC, Khamashta MA, Cardiel M,. Development and validation of an antiphospholipid damage index: A multicenter, binational project. Lupus 1998; 7 (Suppl 1): 68.
15. Amigo MC, Barile LA, Barragán A,. Development and initial validation of a chronic damage index in patients with antiphospholipid syndrome (abstract). Arthritis Rheum 2011; 63 (Suppl): S3-S4.
16. Gladman DD, Urowitz MB,. The SLICC/ACR damage index: Progress report and experience in the field. Lupus 1999; 8: 632-637.
17. Fries JF, Hochberg C, Medsger TA Jr, Hunder GG, Bombardier C,. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1994; 37: 454-462.
18. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
19. Da Rocha Castelar Pinheiro G, Khandker RK, Sato R, Rose A, Piercy J,. Impact of rheumatoid arthritis on quality of life, work productivity and resource utilization: An observational, cross-sectional study in Brazil. Clin Exp Rheumatol 2013; 31: 334-340.
20. Wang C, Mayo NE, Fortin PR,. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001; 28: 525-532.
21. Barbhaiya M, Erkan D,. The optimal tool for assessment of organ damage in antiphospholipid syndrome. J Rheumatol 2013; 40: 89.
22. Vlachoyiannopoulos PG Dr,. Vlachoyiannopoulos replies. J Rheumatol 2013; 40: 90.
23. Swadzba J, Sydor WJ, Kolodziejczyk J, Musial J,. Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies. Lupus 2014; 23: 395-399.
24. Ugolini Lopes M, Aguila L, Tonon R, et al. SLICC and DIAPS: Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). APLA & LACA 2013 14th International Congress on Antiphospholipid Antibodies, 18-21 September 2013, Rio de Janeiro, Brazil.